Sun Pharma Acquisition: Sun Pharma to acquire US-based Organon in $11.75 billion deal, among biggest overseas buys by Indian firms Sun Pharmaceutical Industries announced on Monday that it will acquire US-based Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest overseas acquisitions by an Indian company. The transaction, approved by the boards of both firms, involves Sun Pharma purchasing all outstanding shares of Organon at $14 per share. The deal is expected to close in early 2027, contingent on regulatory clearances and shareholder approval. Following the announcement, Sun Pharma’s shares surged over 7%, rising 7.53% to Rs 1,742 on the BSE and 7.50% to Rs 1,742 on the NSE. The stock rally added Rs 27,462.59 crore to the company’s market valuation, pushing it to Rs 16,142.85 crore in morning trade. The acquisition is positioned as a strategic move to expand Sun Pharma’s global footprint and diversify its portfolio. Organon, a global healthcare firm spun off from Merck & Co. in 2021, operates six manufacturing facilities across the European Union and emerging markets. Its portfolio includes over 70 products spanning women’s health, biosimilars, and general medicines, sold in 140 countries. Post-acquisition, Sun Pharma is projected to enter the top 25 global pharmaceutical companies with combined revenues of $12.4 billion. The company also aims to become a top-three player in global women’s health and the seventh-largest biosimilar company worldwide. Sun Pharma’s executive chairman, Dilip Shanghvi, emphasized the deal’s significance, stating it represents a “significant opportunity” due to Organon’s complementary portfolio and global reach.#sun_pharma #organon_co #dilip_shanghvi #carrie_cox #merck_co
